Rheumatoid arthritis
- PMID: 38240831
- DOI: 10.1016/S0140-6736(23)01525-8
Rheumatoid arthritis
Abstract
Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues. In this Seminar, we provide an overview of the main aspects of rheumatoid arthritis. Epidemiology and advances in the understanding of rheumatoid arthritis pathogenesis will be reviewed. We will discuss the clinical manifestations of rheumatoid arthritis, classification criteria, and the value of imaging in the diagnosis of the disease. The advent of new medications and the accumulated scientific evidence demand continuous updating regarding the diagnosis and management, including therapy, of rheumatoid arthritis. An increasing number of patients are now able to reach disease remission. This major improvement in the outcome of patients with rheumatoid arthritis has been determined by a combination of different factors (eg, early diagnosis, window of opportunity, treat-to-target strategy, advent of targeted disease-modifying antirheumatic drugs, and combination therapy). We will discuss the updated recommendations of the two most influential societies for rheumatology worldwide (ie, the American College of Rheumatology and European Alliance of Associations for Rheumatology) for the management of rheumatoid arthritis. Furthermore, controversies (ie, the role of glucocorticoids in the management of rheumatoid arthritis and safety profile of Janus kinase inhibitors) and outstanding research questions, including precision medicine approach, prevention, and cure of rheumatoid arthritis will be highlighted.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests PE has received grants from Lilly and Samsung; consulting fees from BMS, Boehringer-Ingelheim, Lilly, and Novartis; payment and honoraria from Galapagos, Lilly, and Novartis; support for attending meetings or travel from Lilly; and has participated on a data safety monitoring board or advisory board with AstraZeneca. All other authors declare no competing interests.
Similar articles
-
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.Ann Rheum Dis. 2023 Jan;82(1):95-106. doi: 10.1136/ard-2022-223365. Epub 2022 Nov 11. Ann Rheum Dis. 2023. PMID: 36368906
-
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Arthritis Rheumatol. 2021 Jul;73(7):1108-1123. doi: 10.1002/art.41752. Epub 2021 Jun 8. Arthritis Rheumatol. 2021. PMID: 34101376
-
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.Arthritis Rheumatol. 2017 Aug;69(8):1538-1551. doi: 10.1002/art.40149. Epub 2017 Jun 16. Arthritis Rheumatol. 2017. PMID: 28620948
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Ann Rheum Dis. 2017. PMID: 28264816 Review.
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. Epub 2013 Oct 25. Ann Rheum Dis. 2014. PMID: 24161836 Free PMC article.
Cited by
-
Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis.Front Immunol. 2024 May 15;15:1377911. doi: 10.3389/fimmu.2024.1377911. eCollection 2024. Front Immunol. 2024. PMID: 38812524 Free PMC article.
-
Evaluating sarcopenia prevalence and SARC-F effectiveness in elderly Spanish women with RA: a comparative study of EWGSOP criteria.Front Med (Lausanne). 2024 May 10;11:1392604. doi: 10.3389/fmed.2024.1392604. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38799152 Free PMC article.
-
Effect of Lifestyle Counselling via a Mobile Application on Disease Activity Control in Inflammatory Arthritis: A Single-Blinded, Randomized Controlled Study.Nutrients. 2024 May 14;16(10):1488. doi: 10.3390/nu16101488. Nutrients. 2024. PMID: 38794726 Free PMC article. Clinical Trial.
-
A reconfigurable integrated smart device for real-time monitoring and synergistic treatment of rheumatoid arthritis.Sci Adv. 2024 May 3;10(18):eadj0604. doi: 10.1126/sciadv.adj0604. Epub 2024 May 1. Sci Adv. 2024. PMID: 38691605 Free PMC article.
-
Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test.RMD Open. 2024 Apr 10;10(2):e003927. doi: 10.1136/rmdopen-2023-003927. RMD Open. 2024. PMID: 38599655 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical